CBT-101 (c-Met)

  • An oral specific c-Met inhibitor agent that targets the epithelial to mesenchymal transition (EMT) pathway that is dysregulated in several tumors.
  • c-Met, which is also known as the hepatocyte growth factor receptor, or HGFR, is a signaling pathway that has specific roles in normal mammalian growth and development. However, the HGFR pathway has also been shown to function abnormally in a range of different cancers, primarily through c-Met gene amplification, c-Met over-expression and gene mutations, deletions and insertions. The aberrant activation of c-Met has been demonstrated to be correlated in many cancer indications including kidney, lung, gastric, colorectal, esophageal and brain cancer, and plays a major role in cancer pathogenesis including tumor growth, survival, invasions, and metastasis.
  • Being evaluated in three Phase 1 single trials in the U.S. and in China.
  • Beijing Pearl Biotechnology Co. Ltd. has development rights in China and CBT retains worldwide rights outside China.